Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.6
2.6
Journals
Medicina
Special Issues
Advancement in Oropharyngeal Squamous Cell Carcinoma Diagnosis and Treatment
share announcement

Advancement in Oropharyngeal Squamous Cell Carcinoma Diagnosis and Treatment

A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Oncology".

Deadline for manuscript submissions: closed (30 June 2023) | Viewed by 5837

Special Issue Editor

Prof. Dr. Andrea De Vito

E-Mail Website
Guest Editor
Ear, Nose and Throat (ENT) Unit, Department of Surgery, Lugo Hospital, Health Local Agency of Romagna, Ravenna, Italy
Interests: sleep disordered breathing pathophysiology, diagnosis and therapy; hearing loss diagnosis and surgical treatment; head and neck oncology diagnosis and surgical treatment
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Background and history of this topic: Oropharyngeal squamous cell carcinoma (OPSCC) has reported a constantly increasing incidence in recent years. OPSCC is related to environmental and oncogenic human papillomavirus (HPV) cancer risk factors. Hence, it is possible to identify two main OPSCC patient groups: one induced by environmental cancer risk factors (HPV-negative OPSCC) and the other induced by HPV infection (HPV-positive OPSCC). These two groups of OPSCC patients differ in terms of molecular and genetic profiles, socioeconomic demographics, clinical presentation, treatment options and prognoses in terms of overall survival.

Aim and scope of the Special Issue: The objective of this Special Issue is to provide an up-to-date analysis on the diagnostic workup, clinical presentation and main treatment options of patients affected by OPSCC.
The kinds of papers we are soliciting: narrative reviews, case reports or series as well as retrospective analyses.

Prof. Dr. Andrea De Vito
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • oropharyngeal cancer
  • human papillomavirus
  • narrow-band imaging
  • immunoistochemestry
  • intensity-modulated radiation therapy (IMRT)
  • chemotherapy, trans-oral robotic surgery (TORS)
  • plastic reconstructive surgery
  • oropharyngeal primary unknown cancer

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

10 pages, 697 KiB  
Article
Salvage Post-Operative Stereotatic Ablative Radiotherapy for Re-Current Squamous Cell Carcinoma of Head and Neck
by Antonio Pellizzon, Maria Silva, Ricardo Fogaroli, Elson Neto, Michael Chen, Guilherme Godim, Douglas Castro, Henderson Ramos and Carolina Abrahao
Medicina 2022, 58(8), 1074; https://doi.org/10.3390/medicina58081074 - 10 Aug 2022
Cited by 1 | Viewed by 1440
Abstract
Background and Objectives: Patients with recurrent squamous cell carcinoma of the head and neck (rHNC) face an aggressive disease. Surgical resection is the gold standard treatment. Immediate adjuvant post-operative stereotactic ablative radiotherapy (PO-SABR) for rHNC is debatable. Materials and Methods: We retrospectively [...] Read more.
Background and Objectives: Patients with recurrent squamous cell carcinoma of the head and neck (rHNC) face an aggressive disease. Surgical resection is the gold standard treatment. Immediate adjuvant post-operative stereotactic ablative radiotherapy (PO-SABR) for rHNC is debatable. Materials and Methods: We retrospectively identified patients who were treated with PO-SABR at the AC Camargo Cancer Center, Brazil. Results: Eleven patients were treated between 2018 and 2021. The median time between salvage surgery and PO-SABR was 31 days (range, 25–42) and the median PO-SABR total dose was 40 Gy (range, 30–48 Gy). The 2-and 4-year actuarial DFS were 62.3% and 41.6%, while the 2-and 4-year OS probabilities were 80.0% and 53.3%, respectively. Eight (72.7%) patients were alive and six (54.5%) were without disease at the last follow-up. Two (18.1%) patients had local failure in the PO-SABR field. Three (27.3%) patients had distant metastasis, diagnosed in a median time of 9 months (range, 4–13) after completion of PO-SABR. On univariate analysis, predictive factors related to worse OS were: interval between previous radiotherapy and PO-SABR ≤ 24 months (p = 0.033) and location of the salvage target in the oral cavity (p = 0.013). The total dose of PO-SABR given in more than three fractions was marginally statistically significant, favoring the OS (p = 0.051). Conclusions: Our results encourage the use of a more aggressive approach in selected patients with rHNC by combining salvage surgery with immediate PO-SABRT, but this association needs to be further explored. Full article
(This article belongs to the Special Issue Advancement in Oropharyngeal Squamous Cell Carcinoma Diagnosis and Treatment)
►▼ Show Figures

Figure 1

Review

Jump to: Research

14 pages, 865 KiB  
Review
Surgical Treatment for Advanced Oropharyngeal Cancer: A Narrative Review
by Antonino Maniaci, Sheng-Po Hao, Francesco Cancemi, Damiano Giardini, Emanuele Checcoli, Francesco Soprani, Giannicola Iannella, Claudio Vicini, Salvatore Cocuzza, Ignazio La Mantia, Nicolas Fakhry and Andrea De Vito
Medicina 2023, 59(2), 304; https://doi.org/10.3390/medicina59020304 - 07 Feb 2023
Viewed by 1890
Abstract
Background and Objectives: to describe current scientific knowledge regarding the treatment options in advanced oropharyngeal cancer. The standard care for advanced oropharyngeal cancer (OPSCC) has been chemoradiotherapy, although surgical approaches followed by adjuvant treatment have been proposed. The best therapy for each [...] Read more.
Background and Objectives: to describe current scientific knowledge regarding the treatment options in advanced oropharyngeal cancer. The standard care for advanced oropharyngeal cancer (OPSCC) has been chemoradiotherapy, although surgical approaches followed by adjuvant treatment have been proposed. The best therapy for each patient should be decided by an interdisciplinary tumour-board. Different strategies should be considered for the specific patient’s treatment: surgery, chemotherapy and radiation therapy or combinations of them. The treatment choice is influenced by tumour variability and prognostic factors, but it also depends on cancer extension, extranodal extension, nervous invasion, human papilloma virus (HPV) presence, making the decisional algorithm not always clear. HPV-related OPSCC is strongly associated with a favourable overall survival (OS) and disease-free survival rate (DSS); by contrast, HPV-negative OPSCC often flags a worse prognosis. Consequently, the American Joint Committee on Cancer (AJCC) differentiates OPSCC treatment and prognosis based on HPV status. Methods: we carried out a review of current scientific literature to analyze the different indications and limitations of surgical treatment options in OPSCC stage III and IV. Conclusion: robotic surgery or open approaches with reconstructive flaps can be considered in advanced stages, resulting in the de-intensification of subsequent systemic therapy and fewer related side effects. Furthermore, in the event of the primary failure of systemic therapy or disease recurrence, the surgical approach constitutes an additional therapeutic option which lengthens patient survival functions. Full article
(This article belongs to the Special Issue Advancement in Oropharyngeal Squamous Cell Carcinoma Diagnosis and Treatment)
►▼ Show Figures

Figure 1

12 pages, 336 KiB  
Review
Treatment Options in Early Stage (Stage I and II) of Oropharyngeal Cancer: A Narrative Review
by Giuseppe Meccariello, Andrea Catalano, Giovanni Cammaroto, Giannicola Iannella, Claudio Vicini, Sheng-Po Hao and Andrea De Vito
Medicina 2022, 58(8), 1050; https://doi.org/10.3390/medicina58081050 - 04 Aug 2022
Cited by 3 | Viewed by 1791
Abstract
Objective: to show an overview on the treatments’ options for stage I and II oropharyngeal carcinomasquamous cell carcinoma (OPSCC). Background: The traditional primary treatment modality of OPSCC at early stages is intensity modulated radiation therapy (IMRT). Trans-oral robotic surgery (TORS) has offered as [...] Read more.
Objective: to show an overview on the treatments’ options for stage I and II oropharyngeal carcinomasquamous cell carcinoma (OPSCC). Background: The traditional primary treatment modality of OPSCC at early stages is intensity modulated radiation therapy (IMRT). Trans-oral robotic surgery (TORS) has offered as an alternative, less invasive surgical option. Patients with human papilloma virus (HPV)-positive OPSCC have distinct staging with better overall survival in comparison with HPV-negative OPSCC patients. Methods: a comprehensive review of the English language literature was performed using PubMed, EMBASE, the Cochrane Library, and CENTRAL electronic databases. Conclusions: Many trials started examining the role of TORS in de-escalating treatment to optimize functional consequences while maintaining oncologic outcome. The head–neck surgeon has to know the current role of TORS in HPV-positive and negative OPSCC and the ongoing trials that will influence its future implementation. The feasibility of this treatment, the outcomes ensured, and the side effects are key factors to consider for each patient. The variables reported in this narrative review are pieces of a bigger puzzle called tailored, evidence-based driven medicine. Future evidence will help in the construction of robust and adaptive algorithms in order to ensure the adequate treatment for the OPSCC at early stages. Full article
(This article belongs to the Special Issue Advancement in Oropharyngeal Squamous Cell Carcinoma Diagnosis and Treatment)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop